EUVIMEDEUVIMED entdecken
Open Access

Safety and tolerability of intravenous aprepitant and fosaprepitant in children with cancer: A retrospective, single‐center review

Srivarshini Kanukollu iD, Krisoula Spatz, Jessica A Lavery iD, Julia Glade Bender, Audrey Mauguen, Sherry Mathew

Pediatric Blood & Cancer · 2024

DOI: 10.1002/pbc.30882 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Blood & Cancer, 2024. Verfasst von Srivarshini Kanukollu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Memorial Sloan Kettering Cancer Center, New York, New York, USA. Hauptthemen laut MEDLINE: Antineoplastic Agents, Antiemetics, Neoplasms, Hypersensitivity. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 11 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

NK‐1 receptor antagonists (NK1‐RA) are key agents for chemotherapy‐induced nausea and vomiting (CINV) prevention in patients receiving highly emetogenic chemotherapy. Current pediatric practice guidelines recommend the use of intravenous fosaprepitant or oral aprepitant. However, there are reports of hypersensitivity reactions with fosaprepitant due to polysorbate 80. Intravenous aprepitant does not contain polysorbate 80, but its use in pediatric patients has not been described. In this retrospective, single‐center study, 106 pediatric patients received either fosaprepitant or intravenous aprepitant as part of their antiemetic regimen. Intravenous aprepitant was well tolerated and did not lead to any instances of hypersensitivity reactions requiring discontinuation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsAntiemeticsNeoplasmsHypersensitivityMorpholinesHumansChildAprepitantRetrospective StudiesPolysorbatesVomiting

Stichwörter der Autor:innen

CINVantiemeticsaprepitantfosaprepitantsupportive care

Substanzen

AprepitantfosaprepitantPolysorbatesAntineoplastic AgentsAntiemeticsMorpholines

Autor:innen und Institutionen

  • Department of Pharmacy, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Department of Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.

ORCID-Profile: Srivarshini Kanukollu, Jessica A Lavery

Förderung

  • NCI NIH HHS
  • National Cancer Institute

Zitieren

APA

Kanukollu, S., Spatz, K., Lavery, J. A., Bender, J. G., Mauguen, A., & Mathew, S. (2024). Safety and tolerability of intravenous aprepitant and fosaprepitant in children with cancer: A retrospective, single‐center review. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.30882

Vancouver

Kanukollu S, Spatz K, Lavery JA, Bender JG, Mauguen A, Mathew S. Safety and tolerability of intravenous aprepitant and fosaprepitant in children with cancer: A retrospective, single‐center review. Pediatric Blood & Cancer. 2024. doi:10.1002/pbc.30882

BibTeX
@article{Kanukollu2024,
  author = {Kanukollu, Srivarshini and Spatz, Krisoula and Lavery, Jessica A and Bender, Julia Glade and Mauguen, Audrey and Mathew, Sherry},
  title = {Safety and tolerability of intravenous aprepitant and fosaprepitant in children with cancer: A retrospective, single‐center review},
  journal = {Pediatric Blood & Cancer},
  year = {2024},
  doi = {10.1002/pbc.30882}
}
Kostenlos starten →